Biotechnology

Nascent Biotech, Inc.

Nascent Biotech, Inc. released FY2023 Q4 earnings on June 29 (EST) with actual revenue of 0 and EPS of -0.004

< 1B

1B - 5B

5B - 10B

10B - 50B

50B - 100B

100B - 500B

500B - 1T

≥ 1T

Market Value

Total Assets

< 100M

100M - 500M

500M - 1B

≥ 100B

Revenue

0 - 50M

50M - 100M

≥ 10B

Profits

< 0%

0% - 5%

5% - 10%

10 - 15%

15% - 20%

20 - 25%

25% - 30%

>= 30%

ROE(TTM)

= 0%

0% - 1%

1% - 3%

3% - 5%

5% - 8%

8% - 10%

>= 10%

Dividend Yield

0% - 10%

10% - 15%

20% - 30%

30% - 40%

40% - 50%

>= 50%

Net Profit Margin

0 - 0.05

0.05 - 0.1

0.1 - 0.2

0.2 - 0.4

0.4 - 0.6

0.6 - 0.8

0.8 - 1

>= 1

Asset Turnover

< 1.5

1.5 - 2

2 - 3

3 - 5

5 - 10

10 - 15

15 - 20

>= 20

Equity Multiplier

< 10%

10% - 30%

30% - 50%

50% - 70%

70 - 80%

80% - 90%

90% - 95%

>= 95%

Debt Ratio

Republic Power

Brand Engagement Network

Society Pass

Intelligent Living Application

3 E Network Tech

Globavend

CCSC Tech

Sidus Space

Tryhard

Dreamland

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap

Ownership	%Owned	Share Chg	Report Date
Robert David Burke	14.91%	No Change	31/03/2024
Sean Carrick	13.38%	No Change	30/06/2024
Lowell Holden	6.95%	No Change	30/06/2024
Sidney J. Lorio	5.95%	No Change	31/03/2024
Douglas J. Karas	1.05%	No Change	30/06/2024

Valuation analysis

Institutional View & Shareholder

Analyst Ratings